Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1995 • ACR Convergence 2020
Non-invasive Vagus Nerve Stimulation Improves Signs and Symptoms of Rheumatoid Arthritis: Results of a Pilot Study
Sara Marsal¹, Hector Corominas², Juan Jose De Agustin De Oro³, Carolina Perez Garcia⁴, Maria Lopez Lasanta³, Helena Borrell³, Delia Reina⁵, Raimon Sanmartí⁶, Francisco Javier Narváez⁷, Clara Franco-Jarava⁸, Charles Peterfy⁹, Jose Antonio Narvaez¹⁰, Vivek Sharma¹¹, Konstantinos Alataris¹¹, Mark Genovese¹² and Matthew Baker¹³, ¹Hospital Universitari Vall d'Hebron, Barcelona, Spain, ²Institut Rec. Hospital de la Santa Creu I Sant Pau., Barcelona, Spain, ³Hospital Universitari Vall d’Hebron, Barcelona, Spain, ⁴Hospital Universitari Parc Salut Mar, Barcelona, Spain, ⁵Hospital Moises Broggi, Barcelona, Spain, ⁶Hospital Universitari Clínic de Barcelona, Barcelona, Catalonia, Spain, ⁷Hospital Bellvitge, BARCELONA, Spain, ⁸1Hospital Universitari Vall d’Hebron, Barcelona, Spain, ⁹Spire Sciences, Inc., Boca Raton, FL, ¹⁰Clinica Diagonal, Barcelona, Spain, ¹¹Vorso Corp, Redwood CIty, CA, ¹²Stanford University Medical Center, Palo Alto, CA, ¹³Stanford University, Menlo Park, CA
Background/Purpose: Vagus nerve stimulation (VNS) has been shown to improve rheumatoid arthritis (RA) disease severity in patients with refractory disease (1,2). A multi-center pilot study…
Abstract Number: 2012 • ACR Convergence 2020
A Phase IIb, Randomized, Double-blind Study in Patients with Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared with Placebo in Patients with an Inadequate Response to Methotrexate
Charles Peterfy¹, Maya Buch², Ernest Choy³, Georg Schett⁴, Dana Parsons-Rich⁵, Anand Patel⁶, Yulia Zima⁵, Claire Le Bolay⁷ and Mark Genovese⁸, ¹Spire Sciences, Inc., Boca Raton, FL, ²Centre of Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, United Kingdom, ³CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, ⁴Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, ⁵EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁶EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, ⁷Merck KGaA, Darmstadt, Germany, ⁸Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: Bruton’s tyrosine kinase (BTK) is involved in multiple signalling pathways potentially implicated in rheumatoid arthritis (RA). Evobrutinib is a highly selective, oral BTK inhibitor.…
Abstract Number: 0043 • ACR Convergence 2020
Geographical Disparity in Rheumatoid Arthritis Disease Burden Independent of Race/Ethnicity
Gail Kerr¹, Christopher Swearingen², Manuela Pedra-Nobre³, Dianne Wollaston⁴, Sawsan Najmey⁵, Cynthia Lawrence-Elliott⁶, Theresa Lawrence Ford⁶, Sharon Dowell⁷, Heather North⁸, Robin Dore⁹, Soha Dolatabadi¹⁰, Thaila Ramanujam¹¹, Anne Winkler¹², Stacy Kennedy¹³, Ilona Jileaeva¹⁴, Amina Richardson¹⁵, Jeffrey Kaine¹⁶ and Grace Wright¹⁷, ¹Washington DC VA Medical Center, Washington, DC, ²New York University, New York, NY, ³North Jersey Rheumatology Center, Westfield, NJ, ⁴Memorial Advanced Rheumatology, Inc, HOUSTON, TX, ⁵Midstate Rheumatology Center, Freehold, NJ, ⁶North Georgia Rheumatology Group, Lawrenceville, GA, ⁷Howard University, Washington, DC, ⁸Pardee UNC Rheumatology, Hendersonville, NC, ⁹Private practice, Tustin, CA, ¹⁰Soha Dolatabadi, MD, Los Angeles, CA, ¹¹Thaila Ramanujanm. M.D Inc, Santa Cruz, CA, ¹²Cox Medical Center, Springfield, MO, ¹³Rowan Diagnostic Clinic, Concord, NC, ¹⁴Howard University Hospital, Washington, DC, ¹⁵Howard University College of Medicine, Washington, DC, ¹⁶Sarasota Arthritis Center, Sarasota, FL, ¹⁷Association of Women in Rheumatology, New York, NY
Background/Purpose: In the US, health care systems vary, as does cost sharing and access to various RA therapies. However, the burden of RA – a…
Abstract Number: 0132 • ACR Convergence 2020
Prevalence of Osteoporosis and Fragitlity Fractures Is Not Different Between ACPA Positive Patients Compared to ACPA Negative Patients in a Real World Setting, Despite Longer Disease Duration and Glucocorticoid-Treatment
Edgar Wiebe¹, Desiree Freier¹, Dörte Huscher², Gloria Dallagiacoma³, Sandra Hermann¹, Robert Biesen⁴, Gerd Burmester⁵ and Frank Buttgereit⁶, ¹Charité University Medicine Berlin, Dep. of Rheumatology and Clinical Immunology, Berlin, Germany, ²Charité University Medicine Berlin, Dep. of Biometry and Clinical Epidemiology, Berlin, Germany, ³University of Verona, Dep. of Rheumatology, Verona, Italy, ⁴Charité University Medicine, Dep. of Rheumatology and Clinical Immunology, Berlin, ⁵Charité University Hospital Berlin, Berlin, Germany, ⁶Charité University Medicine, Berlin, Germany
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased systemic bone loss, leading to a high risk for hip, vertebral and non-hip, non-vertebral fractures. Especially ACPA…
Abstract Number: 0158 • ACR Convergence 2020
Relationships Between Disease Patterns in RA and Rheumatology Treatment
Kelly O'Neill¹, Kathryne Marks², John Davis³ and Cynthia Crowson⁴, ¹Rheumatoid Patient Foundation, Orlando, FL, ²Rosalind Franklin University of Medicine and Science, North Chicago, IL, ³Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: We previously showed rheumatoid arthritis (RA) patients report diversity in disease activity (DA) patterns that may be associated with treatment response. Patients who describe…
Abstract Number: 0190 • ACR Convergence 2020
Hepatic Steatosis in Rheumatoid Arthritis: Frequency and Disease-Related Contributors
Jun Lee¹, Galina Lagos², Joan Bathon¹ and Jon Giles¹, ¹Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, ²Columbia University Vagelos College of Physicians and Surgeons, New York
Background/Purpose: Nonalcoholic fatty liver disease (NAFLD), a spectrum of disorders characterized by the presence of hepatic steatosis, is the most common liver disorder in western…
Abstract Number: 0206 • ACR Convergence 2020
Fifty-Two Week Outcomes of Biologic-Naïve RA Patients Treated with Subcutaneous Abatacept in Japanese Multicenter Investigational Study (ORIGAMI Study)
Naoto Tamura¹, Eiichi Tanaka², Eisuke Inoue³, Yuri Yoshizawa⁴, Shigeru Matsumoto⁵, Hisashi Yamanaka⁶ and Masayoshi Harigai⁷, ¹Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Bunkyō, Tokyo, Japan, ²Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ³Department of Rheumatology, Tokyo Women’s Medical University School of Medicine; Showa University Research Administration Center, Showa University, Tokyo, Japan, ⁴Bristol-Myers Squibb K.K., Tokyo, Japan, ⁵Ono Pharmaceutical Co., Ltd., Tokyo, Japan, ⁶Department of Rheumatology, Tokyo Women’s Medical University School of Medicine; Rheumatology, Sanno Medical Center, Tokyo, Japan, ⁷Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan
Background/Purpose: Long-term clinical benefit and patient-reported outcomes (PRO) of subcutaneously-injected abatacept (ABA) in patients with RA in a real-world setting are of therapeutic interest. We…
Abstract Number: 0222 • ACR Convergence 2020
tsDMARD Therapy Is Associated with More Initial Therapy Prolongations Compared to bDMARDs Both in Bionaive and Bioexperienced Patients with Rheumatoid Arthritis
Diederik De Cock¹, Patrick Durez², Dirk Elewaut³, Bernard Lauwerys⁴, Rene Westhovens⁵ and Patrick Verschueren⁶, ¹KU Leuven, Leuven, Belgium, ²Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium, ³Ghent University and VIB, Heusden, Belgium, ⁴Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ⁵University Hospitals Leuven, Belgium, Leuven, Belgium, ⁶University Hospital Leuven, Leuven, Belgium
Background/Purpose: The Tool for Administrative Reimbursement Drug Information Sharing (TARDIS) is an electronic platform combining the collection of data from all Belgian patients with Rheumatoid…
Abstract Number: 0239 • ACR Convergence 2020
Adjudicated MACE and VTE in the Filgotinib RA Program: Integrated Analysis from Phase 2 and 3 Clinical Trials
Christina Charles-Schoeman¹, Sang-Cheol Bae², Arvind Chopra³, Stanley Cohen⁴, Jeffrey R Curtis⁵, Jacques-Eric Gottenberg⁶, Edward C Keystone⁷, Kunihiro Yamaoka⁸, Peter Nash⁹, J-Abraham Simon-Campos¹⁰, William Stohl¹¹, Michael Weinblatt¹², Rene Westhovens¹³, Jeff Siegel¹⁴, Iyabode Tiamiyu¹⁴, Lei Ye¹⁴, Deyuan Jiang¹⁴, Franziska Matzkies¹⁴, Angelika Jahreis¹⁴, John S. Sundy¹⁴ and Jon Giles¹⁵, ¹University of California, Los Angeles, Los Angeles, CA, ²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ³Center for Rheumatic Diseases, Pune, India, ⁴University of Texas Southwestern Medical School at Dallas, and Metroplex Clinical Research Center, Dallas, TX, ⁵Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Strasbourg University Hospital, Strasbourg, France, ⁷Mount Sinai Hospital, Toronto, ON, Canada, ⁸Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan, ⁹School of Medicine Griffith University, Brisbane, Queensland, Australia, ¹⁰Köhler & Milstein Research, Mérida, Mexico, ¹¹University of Southern California Keck School of Medicine, Los Angeles, CA, ¹²Brigham and Women's Hospital, Boston, MA, ¹³University Hospitals Leuven, Belgium, Leuven, Belgium, ¹⁴Gilead Sciences, Inc., Foster City, CA, ¹⁵Columbia University, New York, NY
Background/Purpose: Filgotinib (FIL)—an oral, selective Janus kinase 1 inhibitor (JAKi)—improved RA signs and symptoms in three phase 3 trials. Despite the efficacy of FIL and…
Abstract Number: 0483 • ACR Convergence 2020
Can a Clinical Disease Activity Index Based on Patient-Reported Joint Counts (PT-CDAI) Be Used to Inform Target-Based Care in Telemedicine? An Analysis of 2 Early RA Cohort Studies
Caroline Benson¹, Marie-France Valois², Orit Schieir³, Gregory Vitone¹, Aidan Tirpack¹, Michelle Jones⁴, Louis Bessette⁵, Gilles Boire⁶, Glen Hazlewood⁷, Carol Hitchon⁸, Edward C Keystone⁹, Janet Pope¹⁰, Carter Thorne¹¹, Susan Bartlett², Clifton Bingham III¹², Vivian Bykerk¹ and Canadian Early Arthritis Cohort (CATCH) Investigators¹³, ¹Hospital for Special Surgery, New York, NY, ²McGill University, Montreal, Canada, ³Canadian Early Arthritis Cohort Study, Montreal, Canada, ⁴Johns Hopkins Arthritis Center, Baltimore, MD, ⁵Laval University, Quebec, Canada, ⁶Universite de Sherbrooke, Sherbrooke, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹Mount Sinai Hospital, Toronto, ON, Canada, ¹⁰Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Johns Hopkins University, Baltimore, MD, ¹³Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada
Background/Purpose: COVID-19 mitigation strategies have forced rheumatologists to shift from in-person clinical visits to telemedicine, limiting their ability to carry out complete joint exams needed…
Abstract Number: 0579 • ACR Convergence 2020
Risk Factors of Nonadherence in New Rheumatoid Arthritis Patients
Guy Cozzi¹, Pavlo Kyrychenko², Michele Hamburger³ and Elisea Avalos-Reyes⁴, ¹CVS Health, Northbrook, IL, ²CVS Health, Norhtbrook, IL, ³Frances Hamburger Institute, Hauppauge, NY, ⁴CVS Health, Irving, TX
Background/Purpose: Biologic disease-modifying antirheumatic drug (bDMARD) therapies are commonly prescribed for rheumatoid arthritis (RA) treatment. However, their high out-of-pocket (OOP) cost may limit patient access…
Abstract Number: 0748 • ACR Convergence 2020
Joint Space Narrowing Precedes Erosive Radiographic Damage in Patients with Rheumatoid Arthritis
Andreas Kerschbaumer¹, Gabriela Supp², Farideh Alasti¹, Josef Smolen² and Daniel Aletaha¹, ¹Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, ²Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized through symmetric polyarthritis leading to joint destruction over time in many patients. Radiographic damage is…
Abstract Number: 0766 • ACR Convergence 2020
ACPA and Cholesterol Titers as Predictors of Good Clinical Response at One Year in an Argentine Cohort
Rodrigo Garcia Salinas¹, Alvaro Ruta¹, Santiago Ruta¹, Einer Sanchez Prado¹, Jessica Torres Chichande¹ and Sebastian Magri¹, ¹Hospital Italiano La Plata, La Plata, Argentina
Background/Purpose: Autoantibody positivity, erosions, activity level, and functional capacity were classically defined as poor prognosis. Paradoxically, many of them also predict a good response to…
Abstract Number: 0783 • ACR Convergence 2020
Role of Glutamine Metabolism in Rheumatoid Arthritis Fibroblast-Like Synoviocyte Aggressive Phenotype
Alyssa Torres¹, Brian Pedersen¹, Gary Firestein², Elsa Sanchez-Lopez¹ and Monica Guma³, ¹University of California San Diego, La Jolla, ²University of California, San Diego, La Jolla, CA, ³Division of Rheumatology, University of California San Diego, Department of Medicine, Autonomous University of Barcelona, La Jolla, CA
Background/Purpose: Fibroblast-like synoviocyte (FLS) activation is a key component of rheumatoid arthritis (RA) inflamed synovium. Their aggressive phenotype in RA contributes to initiation and perpetuation…
Abstract Number: 0800 • ACR Convergence 2020
A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of a Proposed High Concentration (100 mg/mL) Adalimumab Biosimilar (CT-P17) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis
Jonathan Kay¹, Janusz Jaworski², Rafal Wojciechowski³, Piotr Wiland⁴, Anna Dudek⁵, Marek Krogulec⁶, Slawomir Jeka⁷, Agnieszka Zielinska⁸, Jakub Trefler⁹, Katarzyna Bartnicka-Maslowska¹⁰, Magdalena Krajewska-Wlodarczyk¹¹, Piotr Klimiuk¹², Daniel Furst*¹³, SangJoon Lee¹⁴, YunJu Bae¹⁴, GoEun Yang¹⁴, JaeKyoung Yoo¹⁴, HyunJin Lee¹⁴ and Edward C Keystone¹⁵, ¹University of Massachusetts Medical School, Worcester, MA, ²Reumatika-Centrum Reumatologii, Warsaw, Poland, ³University Hospital No 2, Bydgoszcz, Poland, ⁴Medical Univeristy, Wroclaw, Poland, ⁵Centrum Medyczne AMED, Warsaw, Poland, ⁶Rheumatology Clinic NZOZ Lecznica MAK-MED, Nadarzyn, Poland, ⁷2nd Univ Hospital, CM UMK, Bydgoszcz, Poland, ⁸Medycyna Kliniczna Marzena Waszczak-Jeka, Warsaw, Poland, ⁹Reuma Centrum, Warsaw, Poland, ¹⁰Centrum Medyczne AMED oddzial w Łodzi, Łódź, Poland, ¹¹University of Warmia and Mazury, Olsztyn, Poland, ¹²Medical University of Białystok and Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk, Białystok, Poland, ¹³Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA, ¹⁴Celltrion, Inc., Incheon, Republic of Korea, ¹⁵Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: CT-P17 (100 mg/mL) is the first proposed biosimilar of the high concentration and citrate-free formulation of reference adalimumab. The purpose of this study was…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].